New Clinical Data Highlights Efficacy of VitaSmart HOPE for Organ Preservation in Transplantation

New Breakthrough in Organ Preservation: The VitaSmart™ HOPE System

Recent clinical research has unveiled significant advancements in the efficacy of the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System for organ transplantation. Presenting at the 2026 Annual Meeting of the American Transplant Congress (ATC) in Boston, this data illuminates how the HOPE system can notably enhance organ preservation, particularly for complex transplants such as those involving the uterus and small intestine.

Understanding HOPE and Its Role in Transplantation

The VitaSmart™ HOPE System is designed to improve the viability of donor organs prior to transplantation. Traditionally, organs face deterioration during the waiting period after retrieval, which can compromise their function upon transplantation. The innovative HOPE technique aims to address this by maintaining the organs in optimal conditions, thereby prolonging their life and functional potential.

As noted by Don Webber, president and CEO of Bridge to Life, "We are committed to advancing the state of organ preservation through the HOPE technology. The newly presented data reinforces the system's versatility and efficacy, expanding its prospects beyond liver transplants in both Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) scenarios."

Clinical Studies Showcase HOPE's Efficacy

Among the new findings, studies from the Cleveland Clinic highlighted the efficacy of HOPE in the preservation of uterus transplants, crucial for treating absolute uterine factor infertility. Traditionally, the use of deceased donor organs for this procedure has been limited. However, researchers found that the HOPE method significantly reduces ischemic injury during preservation, showcasing its potential for future uterus transplant applications.

The study involved preserving uteri from both DBD and DCD donors using the HOPE system for eight hours. Results indicated improved mitochondrial metabolism and reduced markers of ischemic injury compared to traditional methods. This breakthrough moves forward the understanding and possibilities of uterus transplantation, which remains a developing field.

Simultaneously, another study at the Cleveland Clinic compared HOPE with Normothermic Machine Perfusion (NMP) in small intestine transplants. Using discarded grafts, researchers found that HOPE was more effective in preserving mitochondrial and metabolic functions. This not only enhances the organ's viability but also promises better outcomes in transplant procedures, reducing the risks associated with ischemia-reperfusion injury.

Looking Ahead: Expanding the Horizons of Transplantation

The revelations from these studies present a promising opportunity for Bridge to Life to enter new markets, emphasizing the need for improved organ preservation methods and the potential increases in available transplantable organs. As Mauricio Flores Carvalho, vice president of Medical and Scientific Affairs at Bridge to Life, stated: "The challenges we face in organ transplantation often stem from the injury sustained during preservation. HOPE not only protects the organ but also provides real-time assessments of organ viability, revealing an opportunity to convert otherwise unusable organs into viable donors."

Future studies will be pivotal in further validating these findings and broadening HOPE's application across various organ types. The current research is just a preliminary step, and the ongoing investigations will play a crucial role in establishing HOPE not only as a method for liver preservation but potentially for other critical organs as well.

Conclusion

The impact of the VitaSmart™ HOPE System could be transformative for organ transplantation, providing a robust solution to one of the field’s most pressing challenges. With ongoing research and validation, this technology stands poised to change the landscape of organ preservation, ultimately saving more lives through effective transplant procedures. The journey towards broader clinical applications for this promising technology is only just beginning.